ERBB2 and neoplasm: Oncolytic HSV-1 alone did not provide sufficient antitumor effects in a mouse breast cancer model, but treatment with HSV-1 ICP0 lacking KM100 in combination with an efficient ICD inducer, mitoxantrone, significantly improved the survival rate of Her2/neu TUBO-derived tumor-bearing Balb/c mice [119].